120 lines
No EOL
16 KiB
XML
120 lines
No EOL
16 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548748" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548748/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Alfuzosin - LiverTox - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Alfuzosin" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2018/01/08" /><meta name="citation_pmid" content="31644057" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548748/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Alfuzosin" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2018/01/08" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548748/" /><meta name="description" content="Alfuzosin is a nonselective alpha-1 adrenergic antagonist used in the therapy of benign prostatic hypertrophy. Alfuzosin is associated with a low rate of transient serum aminotransferase elevations and with rare instances of clinically apparent acute liver injury." /><meta name="og:title" content="Alfuzosin" /><meta name="og:type" content="book" /><meta name="og:description" content="Alfuzosin is a nonselective alpha-1 adrenergic antagonist used in the therapy of benign prostatic hypertrophy. Alfuzosin is associated with a low rate of transient serum aminotransferase elevations and with rare instances of clinically apparent acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548748/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Alfuzosin/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548748/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8EDECB7D7B38310000000000B0008F.m_5" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid no_max_width">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
|
|
<div class="header">
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<div class="container content">
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548748_"><span class="title" itemprop="name">Alfuzosin</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 8, 2018</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Alfuzosin.OVERVIEW"><h2 id="_Alfuzosin_OVERVIEW_">OVERVIEW</h2><div id="Alfuzosin.Introduction"><h3>Introduction</h3><p>Alfuzosin is a nonselective alpha-1 adrenergic antagonist used in the therapy of benign prostatic hypertrophy. Alfuzosin is associated with a low rate of transient serum aminotransferase elevations and with rare instances of clinically apparent acute liver injury.</p></div><div id="Alfuzosin.Background"><h3>Background</h3><p>Alfuzosin (al fue' zoe sin) is an alpha-1 adrenergic antagonist approved for use in the United States for benign prostatic hypertrophy (but not for therapy of hypertension). Alfuzosin inhibits alpha adrenergic receptors present on smooth muscle in arterioles (called alpha-1b adrenergic receptors), as well as in those in the bladder neck and prostate (alpha-1a adrenergic receptors). The effects of the agent on smooth muscle of the bladder and prostate causes improvement in urine flow in men with partial obstruction due to benign prostatic hypertrophy. Alfuzosin was approved for use in the United States in 2003 for treatment of symptoms of urinary hesitancy due to benign prostatic hypertrophy. Alfuzosin is not approved for use in hypertension. Alfuzosin is available in extended release tablets of 10 mg in several generic forms and under the trade name Uroxatral. The recommended dose is 10 mg with the same meal once daily. Side effects include hypotension, dizziness and syncope (particularly with the initial dose), fatigue, headache, dizziness, palpitations, impotence, incontinence and gastrointestinal upset. Rare, but potentially severe adverse events include postural hypotension, worsening of angina pectoris, priapism and intraoperative floppy iris syndrome.</p></div><div id="Alfuzosin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Alfuzosin has been associated with a low rate of serum aminotransferase elevations (<2%) that in controlled trials was no higher than with placebo or comparative agent therapy. These elevations were transient and did not require dose modification. Since its approval and more wide spread use, several instances of clinically apparent acute liver injury due to alfuzosin have been published. The onset of injury was within 2 to 4 weeks and the pattern of enzyme elevations was predominantly hepatocellular. Prolonged jaundice with evolution to a cholestatic hepatitis was also described. Allergic features of rash, fever and eosinophilia can occur, but are usually not prominent. Autoantibodies are usually not found. Among the various alpha blockers used for hypertension or prostatic hypertrophy, alfuzosin has been most frequently associated with liver injury, but no instances of acute liver failure or vanishing bile duct syndrome have been described with it use.</p><p>Likelihood score: C (probable cause of clinically apparent liver injury).</p></div><div id="Alfuzosin.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of the minor serum aminotransferase elevations and rare instance of clinically apparent liver injury associated with alfuzosin use is not known. Alfuzosin is extensively metabolized by the liver by the cytochrome P450 enzymes (predominantly CYP 3A4) and generation of a mildly toxic intermediate is a possible explanation.</p></div><div id="Alfuzosin.Outcome_and_Management"><h3>Outcome and Management</h3><p>No instances of acute liver failure or chronic liver injury have been reported in association with alfuzosin or other alpha-1 adrenergic blockers. There is no information on cross reactivity of the liver injury among the various alpha-1 adrenergic receptor antagonists, but similarity of chemical structure suggests that cross sensitivity may be present.</p><p>References to the safety and potential hepatotoxicity of alfuzosin are given in the Overview on the Alpha-1 Adrenergic Receptor Antagonists.</p><p>Drug Class: <a href="/books/n/livertox/BPHAgents/">Benign Prostatic Hypertrophy Agents</a></p><p>Other Drugs in the Class:</p><ul><li class="half_rhythm"><div><a href="/books/n/livertox/AlphaBlockers/">Alpha-1 Adrenergic Receptor Antagonists</a>
|
|
<ul><li class="half_rhythm"><div><a href="/books/n/livertox/Doxazosin/">Doxazosin</a>, <a href="/books/n/livertox/Silodosin/">Silodosin</a>, <a href="/books/n/livertox/Tamsulosin/">Tamsulosin</a>, <a href="/books/n/livertox/Terazosin/">Terazosin</a></div></li></ul></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/five-ARIs/">5-Alpha Reductase Inhibitors</a>
|
|
<ul><li class="half_rhythm"><div><a href="/books/n/livertox/Dutasteride/">Dutasteride</a>, <a href="/books/n/livertox/Finasteride/">Finasteride</a></div></li></ul></div></li></ul></div></div><div id="Alfuzosin.PRODUCT_INFORMATION"><h2 id="_Alfuzosin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Alfuzosin.BPI" class="box"><p>
|
|
<b> REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Alfuzosin – Generic, Uroxatral®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Benign Prostatic Hypertrophy Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Alfuzosin" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Alfuzosin.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Alfuzosin_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Alfuzosin.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548748/table/Alfuzosin.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Alfuzosin.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Alfuzosin.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Alfuzosin.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Alfuzosin.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Alfuzosin.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Alfuzosin.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Alfuzosin</td><td headers="hd_h_Alfuzosin.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135061506" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">81403-80-7</a>
|
|
</td><td headers="hd_h_Alfuzosin.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C19-H27-N5-O4</td><td headers="hd_h_Alfuzosin.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<div class="graphic"><img src="/books/NBK548748/bin/Alfuzosin_Structure.jpg" alt="Alfuzosin Chemical Structure" /></div>
|
|
</td></tr></tbody></table></div></div></div><div id="bk_toc_contnr"></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548748</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31644057" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">31644057</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Alemtuzumab/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/Alirocumab/" title="Next page in this title">Next ></a></div></div></div></div>
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK548748&ncbi_domain=livertox&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK548748/?report=printable&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |